Biogen has expanded its specialty immunology pipeline with an agreement to buy Human Immunology Biosciences (HI-Bio) and its lead drug felzartamab, in trials for a range o
Merck & Co (MSD outside the United States) celebrated the tenth anniversary of the first Keytruda approval at ASCO this year, but the company isn’t resting on its laurels.